Showing up is half the battle – predictor of improvement of headache disability

August 14, 2011

At the NYHC, just like at all headache clinics, we see many patients with severe disability. A very interesting study just published in the journal Pain seems to tell us how to predict which of these disabled patients will respond to treatment. Researchers at the Ohio University compared patients whose severe disability improved with treatment and those whose did not. They carefully examined a wide variety of possible factors, including race/ethnicity (African American versus Caucasian American), psychiatric comorbidity, headache management self-efficacy, perceived social support, locus of control, number of headache diagnoses, migraine versus tension-type headache diagnosis, chronic versus episodic headache diagnosis, headache days per month, headache episode severity, and whether the patient attended all scheduled treatment appointments. The only factor that seemed to predict whose disability will improve and whose will not was the attendance of the 3 follow-up visits. Those who came for follow-up visits were much more likely to improve than those who did not – showing up is half the battle.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe